

CHARACTRISATION OF AMINO ACID BIOSYNTHETIC PATHWAYS IN SYNECHOCYSTIS SP. PCC 6803

Primary Supervisor: Dr David Lea-Smith Secondary Supervisor: Dr Andrew Gates

Thesis submitted for the degree of R1C760102 – Biomolecular Science Msc (Res), School of Biology, University of East Anglia

This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived there-from must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution.

> Harry Steward 100213036

Contents

Acknowledgments

I would like to thank my primary supervisor, Dr David Lea-Smith for all the time and effort that he put into ensuring this project was a success and giving me guidance throughout this project. I would like to thank my secondary supervisor Dr Andrew Gates for his guidance during the project also. Also, Dr Jose Angel Moreno Cabezuelo's help with cloning was instrumental in the production of importer plasmids. Dr Lauren Mills insights into the basic biology of *Synechocystis* was also instrumental in this project's success. Dr Andrew Curson, Dr Emese Bartha and Keanu Walsham's help with general lab techniques were extremely helpful in getting my PCR's running properly. I would finally like to thank Joshua Jones for all his help as his assistance was invaluable to this project.

Abstract

Cyanobacteria are one of the most important phyla of organisms on the planet, accounting for 20-30% of global carbon fixation^[1]. Cyanobacteria have a wide array of potential applications in biotechnology. Key to unlocking that potential is gaining a deeper understanding of fundamental biological processes in cyanobacteria, most notably in model species such as *Synechocystis* sp. PCC 6803 (*Synechocystis*). Much of our current understanding of this model organism's central metabolism is based solely on identifying genes with homologs characterised in model heterotrophs. This includes amino acid biosynthesis, which includes several uncharacterised pathways that could be unique to cyanobacteria. A comprehensive understanding of amino acid biosynthesis will enhance their industrial utilisation. To characterise genes encoding enzymes involved in amino acid biosynthesis, this study aims to generate a novel method for generating auxotrophic mutants in *Synechocystis*. Multiple approaches were trialled. Initially mutants were generated using increasing concentrations of kanamycin, eliminating *slr0036* as an essential gene. I then attempted to segregate genes by supplementing media with single amino acids. This approach proved unsuccessful, likely due to the absence of importers or insufficient transport of amino acids into the cytosol. I then attempted to leverage the OppA oligopeptide importer, to import short chain oligopeptides into the cell where they could then be catabolised into their constituent amino acids. This method for compensating for the loss of function of the gene, allowed for successful generation of the *slr1312* and *slr2035* auxotrophic mutants. I tried to allow for import of single amino acids by introducing high affinity *Escherichia coli* (*E. coli*) K12 amino acid importers into Synechocystis, however due to time constraints I was unable to finish this. This study provides an invaluable technique for characterisation of genes encoding proteins involved in amino acid biosynthesis and identification of novel enzymes involved in novel cyanobacterial pathways.

Access Condition and Agreement

Each deposit in UEA Digital Repository is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of the Data Collections is not permitted, except that material may be duplicated by you for your research use or for educational purposes in electronic or print form. You must obtain permission from the copyright holder, usually the author, for any other use. Exceptions only apply where a deposit may be explicitly provided under a stated licence, such as a Creative Commons licence or Open Government licence.

Electronic or print copies may not be offered, whether for sale or otherwise to anyone, unless explicitly stated under a Creative Commons or Open Government license. Unauthorised reproduction, editing or reformatting for resale purposes is explicitly prohibited (except where approved by the copyright holder themselves) and UEA reserves the right to take immediate 'take down' action on behalf of the copyright and/or rights holder if this Access condition of the UEA Digital Repository is breached. Any material in this database has been supplied on the understanding that it is copyright material and that no quotation from the material may be published without proper acknowledgement.

1. Introduction

1.1 Cyanobacteria

Cyanobacteria constitute an ancient and diverse phylum of prokaryotic organisms that have shaped the Earths ecosystems for billions of years. They are found in most ecosystems, contributing 20-30% of global carbon fixation^[1]. Cyanobacteria are capable of conducting oxygenic photosynthesis, utilising the energy primarily for carbon fixation. Photosynthesis primarily occurs in thylakoid membranes^[2], an array of flattened, stacked, interconnected membranes covered in light absorbing complexes termed phycobilisomes. These increase the available surface area for photosynthesis to take place. Cyanobacteria also contain carboxysomes, polyhedral microcompartments which play a vital role in carbon fixation via the 1,5-bisphospate carboxylase/oxygenase (RuBisCO) enzyme^[3]. Many cyanobacteria are also naturally competent and can freely take up exogeneous DNA from the environment^[4].

1.2 Biotechnology applications

Climate change poses a difficult challenge for the global community to overcome. It is driving the need for greater research into more renewable and sustainable solutions to some of mankind's more carbon intensive industries. One technology which promises to help reduce our reliance on $CO₂$ intensive industries is the use of cyanobacteria for absorption of $CO₂$ and biosynthesis of products that would otherwise add to our carbon footprint. Cyanobacteria could be used to produce a vast range of products, from biofuels and bioplastics to high end food and pharmaceutical products^[5].

Biofuels are a promising area of research as the fuel could be used in existing engines. This would help to reduce the economic impact of moving to renewables as existing vehicles and infrastructure could use the fuel with potentially less contribution to climate change ^[6]. This would be especially useful for airlines as there is currently no viable alternative to jet fuel, as modern batteries lack the energy density needed to sustain long flights^[7]. The use of cyanobacteria to produce biofuels would be more sustainable than other biofuel production methods, such as the use of sugar cane, as cyanobacteria can be grown much faster, with minimal nutrients, on non-arable land, without the use of fresh water in photobioreactors or raceway ponds^[5].

Amino acids are precursors to many compounds desired by industry^[8]. They can be used in the production of many dyes, suncreams, pharmaceuticals and much more^{[9][10]}. Redirecting carbon flux via genetic manipulation is key to improving viability of this organisms use in industry. Currently this area of industry, like many others attempting to use cyanobacteria, are struggling with commercialisation. Production of various compounds at scale, is proving extremely difficult. This is not just the case for biofuels but many other industries such as production of suncream and moisturiser derivatives. Skin care products produced via cyanobacteria have been produced in the lab, but production at scale is proving difficult ^[9]. Increased understanding of cyanobacterial central metabolism will allow for manipulation of the genome to more efficiently redirect carbon flux towards production of desired compounds.

1.3 *Synechocystis* sp. PCC 6803

The model organism, *Synechocystis*, is a freshwater autotroph which is naturally competent and can therefore take up free exogenous DNA from its environment [11]. This makes it a good candidate for genetic modification as the cells can more easily be altered to incorporate new genes and plasmids or knockout genes of interest. This is important as significant modification to the cyanobacterial genome will be needed for biosynthesis of products to become economically viable. *Synechocystis* has multiple copies of its genome [12], which can make it challenging to fully segregate a mutant.

Synechocystis is the most widely studied cyanobacterium <a>[13]. Despite this most genes have been assigned function based on homologs characterised in *E. coli* or other heterotrophs [14] . However, many cyanobacterial proteins differ in terms of substrates while other pathways are specific to cyanobacteria.

1.4 Amino acid biosynthesis

Our current understanding of amino acid biosynthesis in cyanobacteria is based solely on homology with heterotrophs^[13] (Figure 1). The majority of pathways have genes with high conservation to those characterised in *E. coli*. However, some *Synechocystis* pathways, such as those synthesising methionine, tyrosine and phenylalanine are not fully characterised due to differences with *E. coli*. Identification of these genes depends on either generating auxotrophic mutants or enzyme assays of likely candidates, which can be challenging to identify via bioinformatics $^{[15][16]}$.

Figure 1: Amino acid biosynthesis in *Synechocystis***.** Amino acids are highlighted, adapted from (Mills, McCormick, & Lea-Smith, 2020). The 20 naturally occurring amino acids are highlighted in red and amino acids that are incorporated into peptidoglycan are highlighted in blue. Auxotropic mutants generated in this project have been underlined in red and partially segregated mutants generated in this project are underlined in green.

1.5 Amino acid and oligopeptide importers

A range of amino acid importer proteins have been characterised in *Synechocystis*[17] *.* The BgtA/BgtB complex transports arginine, histidine, lysine and glutamine (figure 2). The NatABCDE complex transports alanine, glycine, leucine, proline, serine and histidine, and possibly L-cystine ^[18]. Glutamate is transported via GtrABC and GltS . It is unknown whether transporters for the other ten amino acids

are present. In addition, the OppA system transporter, involved in import of peptides generated via peptidoglycan recycling, may also import amino acids or small peptides ^[14] (Figure 3).

Figure 2: Transporters involved in amino acid biosynthesis. Adapted from (Mills, McCormick, & Lea-Smith, 2020).

Figure 3: Peptidoglycan recycling showing the Opp transporter involved in peptide import. Adapted from (Mills, McCormick, & Lea-Smith, 2020).

1.6 Utilising Cyanosource to understand cyanobacterial amino acid biosynthesis The cyanosouce project is a collaboration between the University of East Anglia, the Earlham Biofoundry and the University of Edinburgh, which aims to produce a mutant library for every gene in *Synechocystis* and make available the plasmids required to generate them. This project takes advantage of those cyanosource plasmids to rapidly generate mutants in a range of amino acid biosynthesis pathways. This project seeks to further cyanosouce by determining which of the genes in *Synechocystis* are essential for life and which are not. Amino acid auxotrophic mutants would then be available as part of a mutant library for other groups to use in their own research.

1.7 Aims

Improving our understanding of central metabolism in *Synechocystis* is key to utilising this species and other cyanobacteria in industry. The primary aim of this project is the development of a novel method for generating auxotrophic mutants in biosynthetic pathways in *Synechocystis*. Deletion of genes encoding putative amino acid biosynthesis enzymes was achieved using plasmids sourced through the cyanosouce project. Plasmids allowed for deletion of genes involved in amino acid biosynthesis. A range of techniques were used to try and generate these mutants including using increasing concentrations of kanamycin, supplementing media with single amino acids and compensating for loss of function of the gene with an oligopeptide mixture, N-Z amine. The main obstacles with this project are overcoming the lack of high affinity amino acid importers present in the cell surface membrane of *Synechocystis,* and knocking out the gene of interest on every copy of the chromosome. As a secondary aim, I attempted to express high affinity *E. coli* K12 amino acid importers using their natural promotors and terminators.

2. Materials and methods

2.1 BGII media

BGII medium was prepared according to Lea-Smith, Vasudevan, & Howe, 2016. Appendix table 1 shows the components used.

2.2 Transformation of premade plasmids into *Synechocystis*

Plasmids were generated by the CyanoSource project, containing a CodA/Kan cassette between an up and down flank, complementary to the regions flanking the gene targeted for deletion. These parts were integrated into a pUC19 plasmid. These plasmids were then transformed into *Synechocystis* according to Lea-Smith, Vasudeva, Howe 2016^[19].

A fresh wild-type Synechocystis colony was used to inoculate 30-50 mL of liquid BGII medium. Cultures were then grown for 2-3 days to OD_{750nm} = 0.2 to 0.6, at 30°C. 1-2 mL of media was then centrifuged at 2,300 x g for 5 minutes. The supernatant was then discarded, and the pellet washed with fresh BGII liquid medium to a final volume of 100 μ l. ~1 μ g of pUC19 was then added to the cells and mixed by gently tapping. Tubes were then laid horizontally in the incubator for 4-6 hours at 30°C. Aliquots of 20 and 80 µl of the culture/plasmid mixture were then plated onto separate BGII plates without antibiotics. Plates were then incubated for ~24 hours at 30°C. 2.5-3 mL of 0.6% agar solution containing 100 µg/mL of kanamycin was then cooled to ~42°C and added to the top of the agar. Plates were then incubated at 30°C until colonies were visible, which took approximately 7 days. Individual colonies were then plated on BGII + Kanamycin, 30 μ g/mL agar plates split into 6 sections with separate colonies on each section.

2.3 Verification of mutants

Mutants were verified using PCR and gel electrophoresis. Primers designed for amplification of flanking regions during the construction of plasmids by CyanoSource were used for the verification of mutants (Appendix table 2). Template DNA was obtained by adding cells collected from plates using a toothpick, which was added to 50 μ L of dH₂O. This would then be mixed using the toothpick until the solution was a homogeneous green colour.

PCR components per 25 µL reaction were set up as follows, 1.5 µL buffer containing 25 mM MgCl₂, 1.5 µL 1.25 mM DNTPs (0.075 mM final concentration), 0.2 µL 100% DMSO, 0.25 µL sigma polymerase (1 unit/mL), 1.5 μ L 50 μ M forward primer (3 μ M final concentration), 1.5 μ L 50 μ M reverse primer (3 μ M final concentration), 1 μ L of template DNA and 17.55 μ L distilled water. Components were then mixed gently and placed into a thermocycler. The following amplification protocol was used: 30 cycles of denaturation, annealing and extension, with the following temperatures and times. Initial denaturation, 30 seconds at 98°C. Denaturation, 10 seconds at 98°C. Annealing, 10 seconds at 60°C. Extension, 4 minutes at 72°C. Final extension, 7 minutes at 72°C. Reactions were then held at 12°C.

2.4 Generation of segregated mutants

Transformants were streaked out on BGII containing increasing concentrations of kanamycin in order to generate segregated mutants. These concentrations were 100, 200 and 300 μg/mL of kanamycin. Appropriate amino acids were added to plates at either 5 μg/mL or 50 μg/mL. The peptide N-Z amine was added at concentrations of 300 μg/mL, 600 μg/mL, 1mg/mL and 6 mg/mL. The amino acids in N-Z amine are listed in appendix table 3.

2.5 Production of single amino acid importer plasmids

Primers for amplifying *E. coli* K12 amino acid importers were designed using Primer3 to include the gene(s) and natural promoter and terminator (Appendix table 4). PCR products were generated using AccuTaq polymerase and if this was unsuccessful, Q5 polymerase. Components for AccuTaq PCR reactions were per 50 μL reaction: 5 μL AccuTaq buffer, 2.5 μL of 1.25 mM DNTPs (75 µM final concentration), 5 μL template DNA, 1 μL 100% DMSO, 1 μL 50 μM forward primer (1 μM final concentration), 1 µL 50 µM reverse primer (1 µM final concentration), 34 µL Milli-Q water, 0.5 μL AccuTaq polymerase (1 unit/mL). The following amplification protocol was used: Initial denaturation, 30 seconds at 98°C; Denaturation, 15 seconds at 94°C; Annealing, 20 seconds at 65°C; Extension, 4 minutes at 68°C; Final extension, 6 minutes at 72°C. Components for Q5 PCR reactions per 50 µL reaction were: 0.25 μL Q5 polymerase (1 unit/mL), 5 µl 5 x Q5 buffer, 5 x Enhancer, 0.5 μL 1.25 mM DNTPs (12.5 µM final concentration), 10.75 μL Milli-Q water, 25 μL template DNA, 1.25 μL 50 µM forward primer (1.25 µM final concentration), 1.25 μL 50 µM reverse primer (1.25 µM final concentration) and 1 μL 100 % DMSO. The following amplification protocol was used: Initial denaturation, 30 seconds at 98°C; Denaturation, 10 seconds at 98°C; Annealing, 30 seconds at 62°C; Extension, 4 minutes at 72°C; Final extension, 2 minutes at 72°C.

Inserts were cloned into the shuttle plasmid pCAT.011 via restriction enzyme digest and ligation. Appendix table 5 shows the restriction enzyme for assembly. Assembly and ligation components per 25 μL reaction were: 1 μL pCAT.011 plasmid, 10 μL generated insert, 2 μL ligation buffer 10x, 1 μL BpiI, 1 μL ligase, 2.5 μL Milli-Q water and 2 μL Bsa 10x. Components then underwent assembly and ligation in a single step. Step 1: 5 minutes at 37°C; step 2: 5 minutes at 16°C. Steps 1 and 2 were then repeated 34 times. After 34 cycles, Step 3: 5 minutes at 60°C; step 4: 5 minutes at 12°C. The assembly product was then transformed into *E. coli* DH5α using the method outlined in appendix 6. Transformants were plated on LB media containing 100 μg/mL of spectinomycin and 40 μg/mL of X-Gal. Plates were incubated overnight at 37°C and white cells were then selected for verification. This was done via PCR and restriction enzyme digestions on the purified plasmids. Correct plasmids were then purified using a GeneClean® III kit according to the manufacturer's instructions.

3. Results

3.1 Generation of partially segregated mutants using kanamycin

I first tried to generate mutants of genes encoding enzymes in amino acid biosynthesis pathways by plating partially segregated mutants on increasing concentrations of kanamycin. This selects for cells with the antibiotic resistance cassette inserted into all chromosomes, if the gene is non-essential. Initially, *slr1133*, encoding argH, which catalyses the last reaction of the arginine biosynthesis pathway, was targeted. Despite re-streaking the mutant on plates containing 300 μg/mL of kanamycin, the strain was only partially segregated, as evident by the presence of bands corresponding to the wild-type and knockout profile (Figure 4).

However, two genes, *slr0036* and *sll1683*, were knocked out via this method (Figure 5 and 6, respectively). *slr0036* encodes for a putative AspC, which catalyses the reversible conversion of 2 oxoglutarate and L-aspartate to L-glutamate and oxaloacetate. An additional AspC candidate encoded by *sll0402* is also present in *Synechocystis*[14] , and the non-essentially of *slr0036* suggests this may be the main or only enzyme catalysing this reaction. *sll1683* encodes for the lysine decarboxylase (cad) catalysing conversion of L-lysine to cadaverine. Non-essentially of this gene suggests cadaverine is not required for *Synechocystis* viability.

Figure 4: Generation of a partially segregated *Δslr1133* **mutant.** Mutants grown on BGII media containing 300 μg/mL of kanamycin were tested. Primers flanking the region targeted for deletion

were used for amplification. Expected band size in brackets. Lane 1: NEB 1 kb plus DNA ladder; Lane 2: wild-type (1653 bp), lane 3: Δ*slr1133* mutant (2949 bp).

Figure 5: Generation of a fully segregated *Δsll1683* **mutant.** Mutants were generated on BGII media containing 300 μg/mL of kanamycin. Primers flanking the region targeted for deletion were used for amplification. Expected band size in brackets. Lane 1: GeneRuler 1 kb plus DNA ladder; Lane 2: wildtype *sll1683* (2510 bp); Lane 3: *Δsll1683* (3819 bp).

Figure 6: Generation of a fully segregated *Δslr0036* **mutant.** Mutants were generated on BGII media containing 300 μg/mL of kanamycin. Primers flanking the region targeted for deletion were used for amplification. Expected band size in brackets. Lane 1: GeneRuler 1 kbp plus DNA ladder; Lane 2: wildtype (2374 bp); Lane 3: *Δslr0036* (3963 bp).

3.2 Producing partially and fully segregated mutants using single amino acids

Next, I tried to generate auxotrophic mutants by segregating strains on media supplemented with the appropriate amino acid(s). Two concentrations were tested, 5 μg/mL and 50 μg/mL. *Synechocystis* grew on either of these concentrations for the following amino acids: proline, tryptophan, aspartate, serine, arginine, threonine and tyrosine. However, lysine proved to be toxic to wild-type *Synechocystis*, and inhibited growth on plates containing even 5 μg/mL. Supplementation with amino acids did not result in production of any fully segregated auxotrophic mutants for any of the genes investigated.

Figure 7: Generation of mutants on medium containing single amino acids and kanamycin 300 μg/ml. Primers used were designed to flank the region targeted for deletion. Mutants were generated on BGII media containing a single peptide concentration of 5 and 50 μg/mL and 300 μg/mL of kanamycin. Expected band size in brackets. Lane 1: NEB 1 kb plus DNA ladder; lane 2, 3, 4: failed amplification of wild-type and mutant *sll1883*; lane 5: wild-type *slr0036* (2374 bp); lane 6: *Δslr0036* 5 μg/mL Aspartate (3963 bp); Lane 7: *Δslr0036* 50 μg/mL Aspartate (3963 bp); lane 8: wild-type *sll0402* (2229 bp) with off target sequence (~1400 bp); Lane 9: *sll0402* partial knockout 5 μg/mL Aspartate (3818 bp); lane 10: *sll0402* partial knockout 50 μg/mL Aspartate (3818 bp); lane 11: wild-type *slr2035* (2047 bp); Lane 12: *slr2035* partial knockout 5 μg/mL Proline (3694 bp); Lane 13: *slr2035* partial knockout 50 μg/mL Proline (3694); lane 14: wild-type *sll1662* (1947 bp); Lane 15: *sll1662* partial knockout 5 μg/mL Phenylalanine (3814 bp); Lane 16: *sll1662* partial knockout 50 μg/mL Phenylalanine (3814 bp).

Table 1: List of genes targeted for deletion. Fully segregated genes have been highlighted in yellow.

3.3 Generation of segregated mutants by culturing strains on medium supplemented with an oligopeptide mixture

I first determined whether *Synechocystis* could importing peptides found in N-Z-amine. To do this *Synechocystis* was cultured on medium with various concentrations of N-Z-amine in the presence of NaNO³ or absence of any other nitrogen sources (Figure 8). *Synechocystis* demonstrated growth on all plates which was robust on concentrations higher than 600 μg/ml, showing that a robust system of peptide import is present. For future work we used plates with a concentration of 1 mg/mL N-Z-amine.

6 mg mL-1 peptides 1 mg mL-1 peptides 600 µg mL-1 peptides 300 µg mL-1 peptides

Figure 8: Growth of *Synechocystis* **on BG11 medium supplemented with N-Z-amine at different concentrations.** The top row of plates were grown with sodium nitrate while the bottom row of plates were grown in the absence of sodium nitrate. Concentrations of N-Z-amine used in each plate are shown at the top.

I next tried segregating mutants on medium supplemented with 1 mg/mL N-Z-amine. This method resulted in generation of two auxotrophic mutants in two separate pathways: *slr2035* encoding for ProB, the first enzyme in the proline biosynthesis pathway, and *sll1883*, encoding for ArgJ, the first enzyme in the arginine biosynthesis pathway (Figure 9).

Figure 9: Generation of fully segregated mutants, *Δslr***0036,** *Δslr***1312 and** *Δslr***2035.** Primers used were designed to flank the region targeted for deletion. Mutants were generated on BGII media containing an oligopeptide mixture without sodium nitrate. Expected band size in brackets. Lane 1, 4, 7: GeneRuler 1 kbp plus DNA ladder; Lane 2: wild-type *slr0036* (2374 bp); lane 3: *Δslr0036* (3963 bp); lane 5: wild-type *slr1312* (2812 bp); lane 6: *Δslr1312* (3684 bp); lane 8: wild-type *slr2035* (2047 bp); lane 9: *Δslr2035* (3694 bp).

Although two genes were fully segregated using this method (figure 9 and 10), many other genes remained partially segregated (Figure 11). These include *sll1683* (figure 11),*slr0738* and *sll1883* (figure 10). Many mutants lack a PCR product corresponding to the knockout profile, including *slr0702, sll1908, sll1662, slr1312, slr0055* and *sll0900.* Although a segregated *sll1883* knockout was obtained (Figure 11), the plate became contaminated and had to be discarded and I lacked time to replicate this (Figure 10).

Figure 10: Generation of partially segregated mutants using an oligopeptide mixture and kanamycin 300 μg/ml. Primers used were designed to flank the region targeted for deletion. Mutants were generated on BGII media containing an oligopeptide mixture and 300 μg/mL of kanamycin in the BGII media. Expected band size in brackets. Lane 1: NEB 1 kb plus DNA ladder; lane 2: wild-type *sll1058* (1685 bp); lane 3: mutant *sll1058* (3699 bp); lane 4: wild-type *slr0738* (2508 bp); lane 5: mutant *slr0738* (3777 bp); lane 6: wild-type *sll1908* (2724 bp); lane 7: mutant *sll1908* (3821 bp); lane 8: wild-type *sll0900* (1727 bp); lane 7: mutant *sll0900* (3855 bp); lane 10: wild-type *sll1662* (1947 bp); lane 11: mutant *sll1662* (3814 bp); lane 12: wild-type *slr2035* (2047 bp); lane 13: mutant slr2035 (3694 bp); lane 14: wild-type *sll1883* (2420 bp); lane 15: mutant *sll1883* (3919 bp).

 $\overline{2}$ $\overline{3}$ 5 6 8 9 10 11 12 13 14 15 16 17 18 19 1 Δ 7

Figure 11: Generation of partially segregated mutants using an oligopeptide mixture and kanamycin 300 μg/ml. Primers used were designed to flank the region targeted for deletion. Mutants were generated on BGII media containing an oligopeptide mixture and 300 μg/mL of kanamycin in the BGII media. Expected band size in brackets. Lane 1: NEB 1 kb plus DNA ladder; lane 2: wild-type *sll0402* (2229 bp); lane 3: mutant *sll0402* (3818 bp); lane 4: unsuccessful generation of wild-type *slr1058* PCR product; lane 5: wild-type *slr0702* (2508 bp); lane 6: mutant *slr1058* (3699 bp); lane 7: mutant *slr0702* (3777 bp); lane 8: wild-type *sll1908* (2724 bp); lane 9: mutant *sll1908* (3821 bp); lane 10: wild-type *sll1662* (1947 bp); lane 11: mutant *sll1662* (3814 bp); lane 12: wild-type *sll1883* (2420 bp); lane 13: mutant *sll1883* (3919 bp); lane 14: wild-type *slr1312* (2812 bp); lane 15: mutant *slr1312* (3684 bp); lane 16: wild-type *sll1683* (2510 bp); lane 17: mutant *sll1683* (3819 bp); lane 18: wild-type *slr0055* (1462 bp); lane 19: mutant *slr0055* (3815 bp).

3.4 Confirmation that *slr2035* is an essential gene in the absence of proline

To confirm whether these are auxotrophic mutants we streaked out the *Δslr2035* on N-Z-amine free BG11 plates without and with 5 μg/mL proline (figure 12). The auxotrophic mutants were unable to grow on these plates, suggesting that the cells either lack importers for proline or they demonstrate insufficient activity to compensate for loss of the gene.

Figure 12: *Slr2035* **fully segregated mutants are unable to grow in the absence of the oligopeptide mixture.** The strain was streaked on BGII medium containing 200 μg/mL of kanamycin (Plate A) or BGII media containing 200 μg/mL of kanamycin and 5 μg/mL of proline (Plate B). Plate C shows *slr2035* growing on BGII media supplemented with N-Z-amine and 200 μg/mL of kanamycin, without sodium nitrate.

3.5 Generation of importer gene plasmids

In conjunction with trialling generation of auxotrophic mutants on different supplemented medium, we attempted to generate recombinant *Synechocystis* strains overexpressing *E. coli* amino acid importers (Appendix table 6). This may allow generation of auxotrophic mutants on medium supplemented with individual amino acids. Inserts for importers gene plasmids, GlnQPH, CycA, GltP, YaaJ, DcuB, CadB and ProP were generated using AccuTaq polymerase, whereas BrnQ, GlnQPH, LysP, MetINQ, TdcC, Ansp and arcD were generated using Q5 polymerase.

Figure 13: Generation of importer inserts using AccuTaq. Primers used were designed to flank the importer gene and its natural promoter and terminator. PCR was performed on wild-type E. coli K12. Expected band size in brackets. The top row was generated at an annealing temperature of 60°C and the bottom row was generated at 55°C. Lane 1: GeneRuler 1 kb plus DNA ladder; lane 2: BrnQ (1795 bp); lane 3: AroP (1941 bp); lane 4: GlnQPH (2503 bp); lane 5: HisJQPM (3482 bp); lane 6: LysP (1943 bp); lane 7: CadB (1618 bp); lane 8: CycA (1764 bp); lane 9: GltP (1588 bp); lane 10: YaaJ (1742 bp); lane 11: MetINQ (2774 bp); lane 12: TdcC (1404 bp); lane 13: DcuB (1905 bp); lane 14: AnsP (1873 bp); lane 15: ArcD (1609 bp); lane 16: ProP (1899 bp); lane 17: TcyP (1511 bp).

I was unable to show insertion of the importer gene into the plasmid via restriction enzyme digest due to the low plasmid copy number of pCAT .011 (Appendix table 5). Instead, PCR was performed on the purified plasmid using the primers designed to amplify the importer gene. I was unable to transform these plasmids into *Synechocystis* due to time constraints. However, all plasmids were generated except for those with the HisJQPM and TcyP inserts.

Figure 15: Verification of successful generation of plasmids containing importer genes. Primers used were designed to flank the importer gene and its natural promoter and terminator. PCR was performed on purified plasmids. Expected band size in brackets. Lane 1: GeneRuler 1 kb plus DNA ladder; lane 2, 3, 4: LysP (1943 bp); lane 5, 6, 7: BrnQ (1795 bp); lane 8, 9, 10: AnsP (1873 bp); lane 11, 12, 13: ArcD (1609 bp); lane 15 ,16, 17: AroP (1941 bp); lane 18, 19, 20: TdcC (1404 bp); lane 21, 22, 23: MetINQ (2774 bp).

100213036/2

4. Discussion

In this study to the best of my knowledge produced the first amino acid auxotrophic mutant in *Synechocystis*. Auxotrophic mutants were generated of genes encoding enzymes in two separate pathways, suggesting that this method could be used to generate further mutants in some of the other pathways. I have also showed that *Synechocystis* can grow on an oligopeptide mixture as its soul source of nitrogen, suggesting that oligopeptide importers are present in the plasma membrane. Although this method was successful in generating auxotrophic mutants in two separate pathways, it was not successfully used to generate auxotrophic mutants for 15 other genes. A possible reason for this issue is the relative abundance of certain amino acids in the N-Z amine mixture may have been too low to compensate for loss of function of the gene. Another possibility is the unknown peptidases in *Synechocystis* may have only cleaved certain peptides and released only a subset of amino acids in sufficient quantities. Future studies should utilise other peptide mixtures, which may contain and release higher amounts of other amino acids.

An additional outcome of this study was generation of a cadaverine deficient mutant. Although this gene is not involved with amino acid biosynthesis, it may be lead to lysine toxicity, which should be tested in the future. The function of cadaverine has not been determined in cyanobacteria and future studies are required to investigate this, with phenotypic studies of this mutant a first step.

I was also able to generate plasmids expressing *E. coli* amino importers. While I was unable to transform any plasmids into *Synechocystis* due to time issues, any mutants which demonstrate expression of the importers may be useful for generating auxotrophic mutants in pathways for which supplementation with peptides is insufficient. However, the importer will have to be inserted into the plasma membrane in the correct orientation.

Overall, this study successfully pioneered a novel method for generating auxotrophic mutants in cyanobacteria. Due to time constraints, I was unable to replicate my results in more amino acid biosynthesis pathways. Future studies should focus particularly on trying to generate auxotrophic mutants of the known genes in the methionine, tyrosine and phenylalanine pathways. Combined with bioinformatics study, primarily comparative genomics, this method could then be used to identify the unknown genes in these pathways.

5. References

- 1. Pisciotta, J. M., Zou, Y., & Baskakov, I. V. (2010). Light-Dependent Electrogenic Activity of Cyanobacteria. *PLoS ONE*, 1-10.
- 2. van Eerden, F. J., de Jong, D. H., de Vries, A. H., Wassenaar, T. A., & Marrink, S. J. (2015). Characterization of thylakoid lipid membranes from cyanobacteria and. *Biochimica et Biophysica Acta*, 1319-1330.
- 3. Kerfeld, C. A., & Melnicki, M. R. (2016). Assembly, function and evolution of cyanobacterial carboxysomes. *ScienceDirect*, 66-75.
- 4. Schirmacher, A. M., Hanamghar, S. S., & Zedler, J. A. (2020). Function and Benefits of Natural Competence in Cyanobacteria: From Ecology to Targeted Manipulation. *Life*, 1-15.
- 5. Abed, R., Dobretsov, S., & Sudesh, K. (2009). Applications of cyanobacteria in biotechnology. *Journal of Applied Microbiology*, 1-12.
- 6. Nozzi, N. E., W. K, J., & Atsumi, S. (2013). Cyanobacteria as a platform for biofuel production. *Frontiers in bioengineering and biotechnology*, 1-6.
- 7. Kallio, P., Pasztor, A., Akhtar, M., & Jones, P. R. (2014). Renewable jet fuel. *Current Opinion in Biotechnology*, 50-55.
- 8. Ivanov, K., Stoimenova, A., Obreshkova, D., & Saso, L. (2014). Biotechnology in the Production of Pharmaceutical Industry Ingredients: Amino Acids. *Biotechnology & Biotechnological Equipment*, 3620-3626.
- 9. Derikvand, P., Llewellyn, C. A., & Purton, S. (2016). Cyanobacterial metabolites as a source of sunscreens and moisturizers: a comparison with current synthetic compounds. *European Journal of Phycology*, 43-56.
- 10. Yin, Z., Hu, W., Zhang, W., Konno, H., Moriwaki, H., Izawa, K., . . . Soloshonok, V. A. (2020). Tailormade amino acid-derived pharmaceuticals approved by the FDA in 2019. *Amino Acids*, 1227–1261.
- 11. Cohen , Y., & Gurevitz, M. (2006). The Cyanobacteria—Ecology, Physiology and. *Prokaryotes*, 1074– 1098.
- 12. Schneider, D., Fuhrmann, E., Scholz, I., Hess, W. R., & Graumann, P. L. (2007). Fluorescence staining of live cyanobacterial cells suggest non-stringent chromosome segregation and absence of a connection between cytoplasmic and thylakoid membranes. *BMC Cell Biology*.
- 13. Gale, G. A., Schiavon Osorio, A. A., Mills, L. A., Wang, B., Lea-Smith, D. J., & McCormick, A. J. (2019). Emerging Species and Genome Editing Tools: Future Prospects in Cyanobacterial Synthetic Biology. *Microorganisms*, 1-36.
- 14. Mills, L. A., McCormick, A. J., & Lea-Smith, D. J. (2020). Current knowledge and recent advances in understanding metabolism of the model cyanobacterium Synechocystis sp. PCC 6803. *Bioscience reports*, 1-33.
- 15. Lai, M. C., & Lan, E. I. (2015). Advances in Metabolic Engineering of Cyanobacteria for. *Metabolites*, 636-658;.
- 16. Maestri-El Kouhen, O., & Joset, F. (2002). Biosynthesis of the Branched-Chain Amino Acids in the Cyanobacterium Synechocystis PCC6803: Existence of Compensatory Pathways. *Current Microbiology*, 94-98.
- 17. Quintero, M. J., Montesinos, M. L., Herrero, A., & Flores, E. (2001). Identification of Genes Encoding Amino Acid Permeases by Inactivation of Selected ORFs from the Synechocystis Genomic Sequence. *Genome research*, 2034-2040.
- 18. Suginaka, K., Yamamoto, K., Ashiida, H., Kano, Y., Saw, Y., & Shibata, H. (1998). Cysteine Uptake for Accumulation of Glutathione by the Cyanobacterium Synechocystis strain PCC 6803. *Biosci. Biotechnol. Biochem.*, 424–428.
- 19. Lea-Smith, D. J., Vasudevan, R., & Howe, C. J. (2016). Generation of Marked and Markerless Mutants in Model Cyanobacterial Species. *Jove*.
- 20. Zhou, Z., & Zhou, Z. A. (2020). Escherichia coli K-12 Lacks a High-Affinity Assimilatory Cysteine Importer. *Ecological and Evolutionary Science*.

6. Appendix

Appendix table 1: components for BG11 growth media in accordance with Lea-Smith, Vasudevan, & Howe, $2016^{[19]}$.

Appendix table 2: primers used for verification of mutants. Primers generated by CyanoSource, originally used to generate the plasmids. Lower case letters are restriction enzyme digest sites used in plasmid construction by CyanoSource.

Appendix table 3: concentration of amino acids in N-Z amine. The average MW is approximately 250 Da. The MW distribution is 54% at 100-200 Da, 36% at 200-500 Da, and 9% at 500-1000 Da. (average MW of a single amino acid is 110Da)

Appendix table 4: nucleotide sequence for importer genes

Appendix table 5: nanodrop measurements of the concentration of nucleic acids found in plasmid purification from importer genes found in *E. coli*.

Appendix table 6: list of high affinity importers found in *E. coli* K12^[20], all genes used in this project have been highlighted and a list is also available in appendix 5.

Appendix table 7: list of importer genes from *E. coli* DH5α with expected band sizes and restriction enzyme cut sites added.

Nickie's Quick Competent Cells

- Pick single colony from plate
- Set up overnight culture
- Inoculate 10 mL LB with 100 µL 0/N culture
- Incubate for 3 h shaking
- Spin down cells
- Resuspend in 10 mL ice cold 100 mM MgCI²
- Leave on ice for 5 min
- Spin down cells
- Resuspend in 1 mL ice cold 100 mM

•Leave on ice for at least 30 min prior to use or (for higher

transformation efficiency) leave overnight

•Cells are competent for 1 or two days (on 2 day competence will be lower)

• This method is not suitable for freezing the cells!

Transformation

Pre-chill Eppendorf tube on ice

- Add 1 µL plasmid
- Add 50 µL competent cells
- Gently mix
- Leave on ice for 30 min
- Heat shock for 2 min in 42°C water bath
- Transfer back to ice for 2 min
- Add 500 µL LB Incubate for at least 1 h at 37°C
- Spread 55 µL on plate labelled 10%
- •Spin down the rest and remove most of the supernatant
- Gently Resuspend the pellet and spread the remaining cell suspension
- on a plate labelled 90%
- Incubate at 37°C overnight

Appendix figure 1: transformation of *E. coli* DH5